The longitudinal history of medicines innovation: Part One
This article is originally published in PharmaPhorum.
Strategies for combination therapy in oncology: Part one – Business as usual
This is the first in a three-part series examining the commercial dynamics surrounding combination therapy in oncology across the US and Europe.
Inflation Reduction Act: Adjustments to medication pricing and reimbursement
This is part two of a three-part series published in Managed Healthcare Executive.
Inflation Reduction Act: Increasing healthcare coverage, reducing healthcare prices. How will it impact manufacturers?
This is part 1 of a three-part series published in Managed Healthcare Executive.
An international comparative analysis and roadmap to sustainable biosimilar markets
This study was originally published in Frontiers in Pharmacology.
Medical affairs evolution
Consultants from CRA’s Life Sciences Practice conducted a survey with n=50 leaders in Medical Affairs to learn from their perspectives on trends and challenges in the industry.
Outlining the need for early reimbursed access to curative therapies
Early access to curative therapies is vital to support the clinical benefits they can provide to both patients and healthcare systems. Early access programs (EAPs) are a mechanism to facilitate faster patient access to curative therapies.
CRA’s Medical Affairs Professional Society (MAPS) Lisbon Roundtable
In May 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders in Lisbon on best practices in transitioning from a function that supports scientific communication and manages relationships with thought leaders to a function that is a strategic leader at the ce
Precision approach to population health can benefit patients and health systems
The European Federation of Pharmaceutical Industries and Associations (EFPIA), in collaboration with the EFPIA Oncology Platform (EOP), commissioned a report by Charles River Associates (CRA) to highlight the role of precision health (PH) and precision medicine (PM) in addressing population healt
France: A step towards more regulated drug prices
2022 was an expensive year for public spending in France, that led to a €18.9 billion debt for the social security system[1]
Takeaways from roundtable discussion on Medical Affairs challenges at MAPS 2023 Global Annual Meeting
In spring 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders to better understand obstacles prohibiting their teams from achieving their vision, in addition to progress made towards overcoming those obstacles.
Medical Affairs Professional Society (MAPS) 2023 EMEA Annual Meeting
The MAPS 2023 EMEA Annual Meeting is taking place in Lisbon, Portgual, May 14-16, 2023.
Viability of European cross-border access opportunities to streamline access to ATMPs
In December 2021, the Regulation on Health Technology Assessment (HTA), as originally proposed by the European Commission, was adopted.[1] The Regulation introduces a pe
An analysis of obesity diagnosis and treatment in Medicare and the associated policy landscape
Obesity is a common, serious, and costly disease that increases people’s risk for morbidity and mortality.[1] It is characterized by ab
Ayushman Ghosh joins CRA's Life Sciences practice
CRA announces that Ayushman Ghosh has joined the company’s Life Sciences Practice as a vice president.
Charles River Associates announces six VP promotions
Charles River Associates announces the promotions of six new vice presidents. Sean Sheridan in CRA’s Intellectual Property Practice,
How COVID-19 could revolutionize the UK pharmaceutical procurement landscape: a DOAC procurement case study
Direct oral anticoagulants (DOACs) are widely used pharmaceutical products which represent a significant cost to the healthcare system.
Collaboration for new therapies: maximizing funding and innovation
How do the public and private sectors collaborate on European medicines R&D and how can we increase the synergies that stem from the involvement of these sectors?
Breaking the time capsule: Life Sciences in 2010 and today
CRA’s Life Sciences Practice team recently analyzed past predictions of industry trends and compared them to what has occurred in the past decade, identified influencing factors and success drivers of these trends, and applied them to current industry predictions to outline what needs to occur fo
The year in review: Updates and trends
In 2022, everyone witnessed intense activity in matters related to supply chain issues, the energy transition, oil & gas, post-M&A disputes, licensing issues, breaches of distribution contracts and increasingly arbitrations deriving from geopolitical issues in Europe and Asia and from com
Rare Disease: A year in review
As more investments have been made in developing and commercializing treatments for rare diseases, the experience and expertise of our CRA teams have grown.
Assessing the impact of rarity on French HTA and pricing decisions
With changes to the pricing and access processes such as the new Accord Cadre and the soon-to-be implemented ATU reform likely to impact pricing and access of orphan products in France, Cécile Matthews,
How eligible patient numbers affect price of rare disease drugs in France
Having recently assessed the relationship between drug price and prevalence of non-oncology rare diseases, CRA’s Cécile Matthews, Bhavesh Patel, and Owen Male explore in greater depth the situation for these orphan drug